Page 3 - Nse

Elara Securities sees up to 60% upside in BEML stock price; here's why

Elara Securities has maintained a 'Buy' on the stock, citing expected double-digit earnings growth during FY25-28E, and a rising order pipeline ensuring steady revenue visibility

ICICI Pru AMC makes solid debut, analysts upbeat on long-term; here's why

Domestic brokerages Equirus Securities and PL Capital have initiated coverage on ICICI Prudential Asset Management Company

KSH International IPO closes today; subscription lags at 35%, GMP flat

KSH International IPO comprises a fresh issue of 10.9 million shares worth up to ₹420 crore and an OFS of 7.6 million equity shares worth up to ₹290

Investing in Gujarat Kidney IPO? Check 5 key risks before you decide

Gujarat Kidney IPO will be offered at a price band of ₹108 to ₹114 per share, with a lot size of 128 shares

Earnings recovery expected to gather pace by FY27: Neelesh Surana

The Indian market has delivered limited returns, with median performance for the NSE 500 turning negative, says Surana

ICICI Sec starts coverage on Leela Palaces with 'Buy'; 45% upside seen

ICICI Securities has set a target price of ₹600 for Leela Palaces Hotels and Resorts, based on a 22x EV/Ebitda on December 2027 earnings estimates for its hotels business

Motilal Oswal retains Buy on Vishal Mega Mart, sees 25% upside; here's why

MOFSL said Vishal Mega Mart's management remains optimistic about sustaining double-digit Same Store Sales Growth on an annual basis for a fairly long period

Park Medi World makes muted debut, lists at 4% discount; miss GMP estimates

Park Medi World shares opened at ₹158.80 on the NSE, a discount of ₹3.2 or 2 per cent from the issue price of ₹162

Corona Remedies makes bumper D-St debut; lists at 38% premium on bourses

Corona Remedies shares opened at ₹1,470 on the NSE, a premium of ₹408 or 38 per cent from the issue price of ₹1,062

Modi Naturals plans up to ₹100 crore FMCG acquisitions after NSE listing

Modi Naturals aims to acquire brands in ready-to-eat and healthy snacks as it grows its FMCG portfolio, saying its NSE listing will improve visibility, liquidity and investor reach

Wakefit Innovations IPO allotment today; check status, GMP, listing date

Applicants can check their Wakefit Innovations IPO allotment status on the official websites of NSE and BSE, or the registrar Kfin Technologies

Meesho lists at 46% premium; analysts upbeat on long-term view; here's why

Choice Equity Broking has initiated coverage on Meesho with a 'Buy' rating, citing the company's structural competitive Moats, strong monetisation runway, and accelerating path to profitability

Vidya Wires makes flat D-street debut at ₹52; misses GMP estimates

Ahead of debut, Vidya Wires shares were quoting at ₹55.5 in the grey market, reflecting a premium of ₹3.5 or 6.7 per cent over the issue price

Meesho IPO to make D-St debut on Dec 10: Here's what latest GMP hints at

Overall subscription for Meesho IPO was strong at 79.03 times, with total bids at 21.96 billion shares against the 277.93 million shares on offer

Sensex falls 800 pts, Nifty below 26k: Why are stock markets falling today?

The BSE Sensex tumbled 803 points in the intraday to hit a low of 84,909, and the NSE Nifty50 also slipped below the 26,000 mark in the intraday to hit a low of 25,902.95

Wakefit Innovations IPO opens today: Check GMP, price band, dates, review

Ahead of its IPO, Wakefit Innovations raised ₹580 crore from 33 institutional investors via an anchor book on December 5

Meesho IPO subscribed 79x; check allotment status, GMP, listing date

Meesho IPO allotment: Applicants can verify their status through the NSE and BSE websites or by visiting the IPO registrar, Kfin Technologies

Indus Towers, Policybazaar among top analyst bets; check target, stop-loss

Indus Towers has consistently traded above all its significant EMAs, reflecting a positive market sentiment, and Policybazaar has also demonstrated a consistent performance

JM Financial starts coverage on KPR Mill with 'Buy'; check target price

JM Financial has set a target price of ₹1,215 per share, implying an upside potential of 21 per cent

Meesho IPO opens Dec 3: Analysts recommend long-term buy; should you bid?

Analysts at SBI Securities and Arihant Capital have recommended that investors subscribe to the Meesho IPO with a long-term perspective.